These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 1619003

  • 1. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia.
    Quarles LD, Lobaugh B, Murphy G.
    J Clin Endocrinol Metab; 1992 Jul; 75(1):145-50. PubMed ID: 1619003
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. A novel mechanism for skeletal resistance in uremia.
    Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A.
    Kidney Int; 2000 Aug; 58(2):753-61. PubMed ID: 10916099
    [Abstract] [Full Text] [Related]

  • 4. PTH-stimulated adenylate cyclase activity and bone histomorphometry in iliac crest biopsies in the evaluation of uremic patients: a pilot study with the use of artificial intelligence.
    Jablonski G, Nordahl K, Halse J, Dahl E, Aksnes L, Gautvik KM, Gordeladze JO.
    Miner Electrolyte Metab; 1993 Aug; 19(6):351-61. PubMed ID: 8164616
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia.
    Slatopolsky E, Cozzolino M, Lu Y, Finch J, Dusso A, Staniforth M, Wein Y, Webster J.
    Kidney Int; 2003 Jun; 63(6):2020-7. PubMed ID: 12753289
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Target range of PTH in uremia].
    Tahara H, Tabata T.
    Clin Calcium; 2004 Jan; 14(1):39-44. PubMed ID: 15576952
    [Abstract] [Full Text] [Related]

  • 11. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients.
    Solal ME, Sebert JL, Boudailliez B, Marie A, Moriniere P, Gueris J, Bouillon R, Fournier A.
    J Clin Endocrinol Metab; 1991 Sep; 73(3):516-24. PubMed ID: 1874930
    [Abstract] [Full Text] [Related]

  • 12. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center study.
    Grey A, Mitnick MA, Shapses S, Ellison A, Gundberg C, Insogna K.
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3450-4. PubMed ID: 8855783
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison between 1alpha(OH)D3 and 1,25(OH)2D3 on the suppression of plasma PTH levels in uremic patients, evaluated by the 'whole' and 'intact' PTH assays.
    Brandi L, Egfjord M, Olgaard K.
    Nephron Clin Pract; 2005 Oct; 99(4):c128-37. PubMed ID: 15722644
    [Abstract] [Full Text] [Related]

  • 15. Serum immunoreactive parathyroid hormone and 25-hydroxyvitamin D in patients with uremic bone diseases.
    Shen F-H, Baylink DJ, Sherrard DJ, Shen L, Maloney NA, Wergedal JE.
    J Clin Endocrinol Metab; 1975 Jun; 40(6):1009-17. PubMed ID: 1133150
    [Abstract] [Full Text] [Related]

  • 16. Comparison of different parathyroid hormone radioimmunoassays in uremic patients with secondary hyperparathyroidism.
    Togashi K, Takahashi N, Ando K, Tsukamoto Y, Marumo F.
    Int J Artif Organs; 1990 Feb; 13(2):77-82. PubMed ID: 2347659
    [Abstract] [Full Text] [Related]

  • 17. Significance of serum magnesium as an independent correlative factor on the parathyroid hormone level in uremic patients.
    Ohya M, Negi S, Sakaguchi T, Koiwa F, Ando R, Komatsu Y, Shinoda T, Inaguma D, Joki N, Yamaka T, Ikeda M, Shigematsu T.
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3873-8. PubMed ID: 24937533
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Serum bioactive parathyroid hormone in hemodialysis patients.
    McCarthy JT, Klee GG, Kao PC, Hodgson SF.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):340-5. PubMed ID: 2918050
    [Abstract] [Full Text] [Related]

  • 20. Parathyroid hormone and mobilization of circulating bone marrow-derived cells in uremic patients.
    Coppolino G, Bolignano D, De Paola L, Giulino C, Mannella A, Riccio M, Mascaro MA, Lombardi G, Fuiano G, Lombardi L, Buemi M.
    J Investig Med; 2011 Jun; 59(5):823-8. PubMed ID: 21383630
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.